Lifestyle Asset Management Inc. Sells 95 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Lifestyle Asset Management Inc. lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 2.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,791 shares of the biotechnology company’s stock after selling 95 shares during the period. United Therapeutics makes up approximately 0.8% of Lifestyle Asset Management Inc.’s portfolio, making the stock its 20th biggest holding. Lifestyle Asset Management Inc.’s holdings in United Therapeutics were worth $1,359,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. LSV Asset Management boosted its position in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Swedbank AB purchased a new position in United Therapeutics in the first quarter valued at about $97,316,000. Canada Pension Plan Investment Board grew its position in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares during the period. Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after purchasing an additional 91,597 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 14,700 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $964,983.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $44,743.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,422 shares of company stock worth $29,229,828 over the last three months. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Argus increased their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. TD Cowen raised their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Finally, Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Trading Up 1.3 %

Shares of United Therapeutics stock opened at $402.57 on Friday. The firm has a market capitalization of $17.97 billion, a PE ratio of 17.68, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $405.98. The business’s 50-day moving average price is $358.27 and its 200-day moving average price is $320.94.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the firm posted $5.38 earnings per share. The business’s revenue was up 22.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.